Molecular Oncology Research Center.
Children and Young Adult's Cancer Hospital.
J Neuropathol Exp Neurol. 2019 Sep 1;78(9):788-790. doi: 10.1093/jnen/nlz066.
Medulloblastoma is the most frequent malignant brain tumor in children, representing 20% of all childhood brain tumors. Currently, medulloblastomas are molecularly classified in 4 subgroups that are associated with distinctive clinicopathological features. KBTBD4 mutations were recently described in a subset of MBGRP3 and MBGRP4 medulloblastomas subgroups. However, no other studies reported KBTBD4 mutations in medulloblastomas. Thus, our aim was to investigate KBTBD4 mutations in a Brazilian series of medulloblastoma. We evaluated 128 medulloblastoma patients molecularly classified from 4 Brazilian reference centers. DNA from formalin-fixed, paraffin-embedded samples was screened for KBTBD4 hotspot mutations by Sanger sequencing. Most of the patients were male, average age was 16.5 years old and average overall survival was 55.9 months. The predominant histological subtype was the classic subtype, followed by nodular/desmoplastic, and the predominant medulloblastoma molecular subtype was the MBSHH subgroup (46%), followed by MBGRP3 and MBGRP4 (19%/each), and MBWNT (16%). Among the 128 samples, 111 were successfully sequenced. No KBTBD4 mutations were identified in 111 samples. Our findings suggest that KBTBD4 mutations are uncommon in Brazilian MBGRP3 and MBGRP4 medulloblastomas subgroups. Further studies in a larger series of MBGRP3 and MBGRP4 medulloblastomas are warranted to better assess role of KBTBD4 mutations.
髓母细胞瘤是儿童最常见的恶性脑肿瘤,占儿童脑肿瘤的 20%。目前,髓母细胞瘤在分子上分为 4 个亚组,与独特的临床病理特征相关。KBTBD4 突变最近在一组 MBGRP3 和 MBGRP4 髓母细胞瘤亚组中被描述。然而,其他研究没有报告髓母细胞瘤中的 KBTBD4 突变。因此,我们的目的是研究巴西一系列髓母细胞瘤中的 KBTBD4 突变。我们评估了来自 4 个巴西参考中心的 128 例分子分类的髓母细胞瘤患者。通过 Sanger 测序对福尔马林固定、石蜡包埋样本的 DNA 进行 KBTBD4 热点突变筛查。大多数患者为男性,平均年龄为 16.5 岁,总生存率平均为 55.9 个月。主要组织学亚型为经典型,其次是结节/促纤维型,主要的髓母细胞瘤分子亚型是 MBSHH 亚组(46%),其次是 MBGRP3 和 MBGRP4(19%/各),和 MBWNT(16%)。在 128 个样本中,有 111 个成功测序。在 111 个样本中未发现 KBTBD4 突变。我们的研究结果表明,KBTBD4 突变在巴西的 MBGRP3 和 MBGRP4 髓母细胞瘤亚组中不常见。需要进一步在更大系列的 MBGRP3 和 MBGRP4 髓母细胞瘤中进行研究,以更好地评估 KBTBD4 突变的作用。